BIOCYTOGEN PHARMA. H YC1 Capital Reinvestment Ratio
BIOCYTOGEN PHARMA. H YC1 capital reinvestment ratio. BIOCYTOGEN PHARMA. H YC1 (I54) has a Capital Reinvestment Ratio of 0.24x as of December 2025, meaning it reinvests 0% of its operating cash flow (€370.25 Million) in capital expenditures (€87.82 Million). Check I54 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of BIOCYTOGEN PHARMA. H YC1 (2024–2025)
Capital reinvestment ratio of BIOCYTOGEN PHARMA. H YC1 from 2024 to 2025. This chart tracks BIOCYTOGEN PHARMA. H YC1's Capital Reinvestment Ratio across 2 annual periods. Also explore BIOCYTOGEN PHARMA. H YC1 (I54) net asset momentum to track the company's year-over-year net asset growth rate.
BIOCYTOGEN PHARMA. H YC1 Capital Reinvestment Ratio by Year (2024–2025)
BIOCYTOGEN PHARMA. H YC1 capital reinvestment ratio by year from 2024 to 2025. For the full cash flow conversion analysis, see BIOCYTOGEN PHARMA. H YC1 operating cash flow efficiency.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.24x | €370.25 Million | €87.82 Million | ▲ +34.9% |
| 2024 | 0.18x | €211.25 Million | €37.13 Million | — |